Genome-Based Diagnostics

Genome-based diagnostics covers everything from a single-gene test to sequencing an entire exome, and the tests differ enormously in what they can actually settle. This guide explains the categories, the evidence bar each has to clear, and how to read a result that comes back uncertain.

Introduction

The connection between the human genome (complete set of your DNA) and medications has been a matter of study for years, however, due to limited evidence, healthcare providers have been cautious in adopting genome-based diagnostics. To ascertain the evidence needed to make these genome-based tests of clinical value, a workshop hosted by the Institute of Medicine’s Roundtable titled “Genome-Based Diagnostics: Clarifying Pathways to Clinical Use” was held in November 2010.

The sequencing of the human genome and the identification of associations between specific genetic variants and diseases have led to an explosion of genomic-based diagnostic tests. These tests have the potential to direct therapeutic interventions and predict the risk or inception of disease. As research progresses and an increasing number of associations are found, further tests will be developed that can aid in providing personalized treatment options for patients.

Despite these advancements, the adoption of genomic diagnostic tests by healthcare providers has been limited due to a lack of evidence regarding the clinical utility of many tests. Health funders and practitioners lack the data necessary to distinguish which tests can improve practice or the clinical settings in which tests will provide the greatest value. The 2010 workshop highlighted the need for better mechanisms to generate this evidence and discussed new models, strategies, and specific actions for developing genomic diagnostic tests of clinical value.

Genome-Based Diagnostics and Pharmacogenomics:

Advancements in Pharmacogenomics have led to the success of genome-based diagnostics and medications. A simple pharmacogenomics test, commonly known as a PGx test, can give insights into your genetic makeup. These reports help doctors tailor drugs and doses based on genome data and avoid medications that can have adverse effects on an individual. An at-home pharmacogenomics test by RPh LABS, requiring just a cheek swab can show you how your body may respond to 240+ medications, and suggest alternates as well.

FDA and Pharmacogenetic Tests

According to the FDA, “Pharmacogenetic tests, along with other information about patients and their disease or condition, can play an important role in drug therapy”. The institution further added that the “knowledge of a patient’s genotype may be used to aid in determining a therapeutic strategy, determining an appropriate dosage, or assessing the likelihood of benefit or toxicity”.

Furthermore, certain drugs are labeled by the FDA as they may affect individuals differently, such as Tetrabenazine (Xenazine) dosages above 50mg per day should be genotyped to know the type of metabolizer a patient is. This drug is primarily metabolized by the CYP2D6 enzyme, thus knowing if someone is a poor or extensive metabolizer guides doctors to administer dosages accordingly and avoid adverse effects.

PGx Tests Insurance Coverage

While pharmacogenomics (PGx) testing may be vital in removing trial and error from medication, especially mental health medication, reimbursements can be tough. The insurance coverage and reimbursement of your PGx testing claims may be subject to the therapeutic condition, the diagnosis code used, and a few more factors.

Keeping in view the coverage difficulties, RPh Labs offers payment in 4 interest-free installments charged whatsoever. Taking a test is easy. Here is how it works.

References:

• Ncbi.Nlm
• Primo

Disclaimer: This blog is for informational purposes. Please always consult a doctor before taking any medical action.

The categories inside genome-based diagnostics

Almost every confusion in this field comes from treating one label as if it covered every test. It helps to separate them by the question each one answers.

• Diagnostic testing asks why someone has symptoms now, for example sequencing a panel of genes in a child with developmental delay.
• Predictive and presymptomatic testing asks about future risk in a healthy person, such as testing for a known familial BRCA1 variant.
• Carrier screening asks whether prospective parents carry recessive conditions.
• Prenatal and newborn screening estimate risk or detect treatable conditions early, and screening is not the same as diagnosis.
• Tumor genomic testing looks at the cancer’s own DNA to find treatment targets.
• Pharmacogenomic testing asks how a person processes medicines, not whether they will become ill.

Those categories differ in who orders them, what counselling is attached, what insurers will cover and what the result means for relatives. Grouping them all as genome-based diagnostics is convenient and it is also how people end up buying the wrong test.

The test types themselves

A single-gene test answers one question cheaply. A panel sequences a defined set of genes chosen for a clinical question. Whole exome sequencing reads the protein-coding regions, and whole genome sequencing reads essentially everything. Broader is not automatically better, because broader also means more uncertain findings.

Clinical utility of genetic tests, and the three questions behind it

The evidence framework that professionals use has three layers, and almost all disagreement about a test lands in one of them.

1. Analytical validity: does the laboratory detect the variant accurately and reproducibly? This is a technical question and it is usually the easiest to satisfy.
2. Clinical validity: does the variant genuinely relate to the condition, and how strongly? This is where many marketed tests are weakest.
3. Clinical utility: does using the test lead to a decision that improves outcomes? This is the hardest bar and the one that matters most to patients and payers.

The clinical utility of genetic tests is exactly what an insurer asks about when deciding coverage, and it is the reason a scientifically real association may still not justify testing. A finding can be true and still change nothing you would do.

There is a fourth consideration that often decides adoption in practice: whether an action exists. A test for a condition with a treatment, a screening program or a medication change gets adopted quickly. A test with no actionable consequence has to justify itself on information value alone.

Whole exome sequencing and what it finds

Whole exome sequencing reads the roughly two percent of the genome that codes for proteins, where a large share of known disease-causing variants sits. It has become a standard tool in diagnosing rare disease, particularly in children with unexplained developmental or neurological problems.

Diagnostic yield is real but partial. Across rare disease cohorts, exome sequencing typically produces a diagnosis in a minority of cases rather than most, and yield depends heavily on how well selected the patient group is.

• Trio testing, sequencing the child and both parents, improves interpretation substantially by showing whether a variant is inherited or new.
• Reanalysis matters. A negative result can become positive years later as knowledge improves, so ask about reanalysis policy.
• Coverage is imperfect. Some regions sequence poorly, and structural variants and repeat expansions are often missed.
• Whole genome sequencing adds non-coding regions and detects some variant types better, at higher cost and with more uncertainty.
• Secondary findings, unrelated to the original question, are reported for a defined list of actionable genes, and you can usually choose whether to receive them.

The decision to sequence and the interpretation of the result both need a clinical genetics service. This is the part of genome-based diagnostics where expert interpretation adds the most value.

How to read a variant of uncertain significance

A variant of uncertain significance, usually shortened to VUS, means the laboratory found a difference from the reference sequence and there is not enough evidence to say whether it causes disease.

It is not a diagnosis, it is not a warning, and it should not drive treatment. That sentence is worth reading twice, because VUS results have led to unnecessary surgery when they were misread as positive.

• Variants are classified on a five-point scale from benign to pathogenic, with uncertain in the middle.
• Most VUS results are eventually reclassified as benign as more data accumulates.
• Reclassification can take years, and laboratories differ in how they recontact patients, so ask.
• VUS results are more common in people from ancestries underrepresented in genetic databases, which is a known equity problem in genome-based diagnostics.
• Family testing sometimes helps, by showing whether the variant tracks with the condition in relatives.

The right response to a VUS is to keep it in the record, continue whatever screening your clinical and family history justify, and ask about reanalysis after a couple of years. A genetic counselor is the right person to interpret it, not a search engine.

Direct to consumer genetic testing and its limits

Direct to consumer genetic testing has introduced millions of people to their own DNA, and the technology behind it is usually genotyping arrays rather than sequencing. That distinction explains most of its limitations.

• An array checks specific pre-selected positions. It does not read a whole gene, so it can miss the overwhelming majority of variants in that gene.
• A widely used example: a consumer report covering three common BRCA variants tells you nothing about the thousands of other pathogenic variants in those genes. A negative result there is not reassurance.
• Health reports are typically labeled as not diagnostic, and that label is accurate.
• Raw data files interpreted by third-party tools produce a high rate of false positives and should never be acted on.
• Any consumer result that matters clinically should be confirmed by a clinical laboratory before it changes anything.
• Privacy terms vary. Read what happens to your data, who it can be shared with, and whether you can delete it.

None of that makes direct to consumer genetic testing worthless. It is a reasonable entry point, and the ancestry side is generally what people enjoy most. The rule is simply that a consumer report is a prompt to talk to a clinician, not a conclusion.

Where pharmacogenomic testing sits in this landscape

Pharmacogenomics is the corner of genome-based diagnostics with an unusually favorable profile on the three-layer framework, because the action is clear when a result is abnormal.

Analytical validity is generally good for the well-characterized genes. Clinical validity is strong for a defined set of gene and drug pairs. Clinical utility is best supported where a specific prescribing change follows, such as an alternative to clopidogrel in a CYP2C19 poor metabolizer, or DPYD testing before fluorouracil.

• It does not predict disease. A pharmacogenomic panel cannot tell you whether you will develop cancer, dementia or heart disease.
• It does not diagnose. Not depression, not ADHD, not any medical condition.
• It covers the genes on the panel. Ours covers 20, reported against more than 240 medications.
• Interacting medicines can override genotype, so the medicine list matters as much as the result.
• The result lasts for life, because your DNA does not change, although the guidance attached to it is updated.

The NHGRI definition of pharmacogenomics and the CPIC guidelines are the reference points, and our introduction to PGx testing covers the basics.

Why adoption has been slower than the science

The gap between what is technically possible and what is used in clinics is wide, and it is not mainly about laboratory capability. Sequencing costs have fallen dramatically while routine use has grown slowly.

• Evidence generation is expensive and slow. Demonstrating that a test improves outcomes usually needs a trial, and trials of diagnostics attract less funding than trials of drugs.
• Clinicians outside genetics receive limited training in interpreting reports, so results arrive without a confident reader.
• Electronic records often cannot store a genotype in a way that triggers an alert later, which is exactly when a pharmacogenomic result is most useful.
• Reimbursement follows evidence, and evidence follows use, which is a circular problem the field has been working through for years.
• Databases underrepresent people of non-European ancestry, which produces more uncertain results and less reliable interpretation for those patients.

There has been real progress on each of these. Implementation programs in health systems have shown that results can be delivered into prescribing workflows, and several professional bodies now publish guidance that clinicians outside genetics can follow.

For patients the practical consequence is simple. Ask where your result will be stored, whether it will be visible to future prescribers, and how you will carry it with you. A report that lives only in an email attachment tends to be forgotten at exactly the moment it mattered.

Coverage, cost and consent

Practical barriers determine who actually benefits from genome-based diagnostics, and they are worth understanding before you order anything.

• Insurance coverage depends on medical necessity criteria, the diagnosis code used and sometimes prior authorization.
• Ask for the specific test name and code, and ask the laboratory about patient responsibility before testing rather than after.
• Federal law prohibits health insurers and employers from using genetic information to discriminate in most circumstances, but it does not cover life, disability or long-term care insurance.
• Consent should cover what will be reported, whether secondary findings are included, how data is stored and whether it may be used for research.
• Genetic counseling improves decisions before testing as well as after, and telehealth counseling has made it far more accessible.

For our own panel: self-pay is $299, HSA and FSA eligible, and can be split into four interest-free installments. Insurance including Medicare, Texas Medicaid and Blue Cross Blue Shield of Texas is accepted, and the insurance page explains billing. Results come 7 to 10 business days after the sample reaches the lab, from a cheek swab processed in a CLIA-certified and COLA-accredited laboratory in Dallas, Texas.

Questions to ask before any genetic test

One short list prevents most disappointments, whichever test is being proposed.

1. What question will this answer, and what would change depending on the result?
2. Which genes or variants are covered, and what is not covered?
3. How likely is an uncertain result, and what happens if I get one?
4. Who interprets the report, and will I have access to a genetic counselor?
5. What does it cost me, and has coverage been checked in advance?
6. What happens to my data, and can I withdraw it later?

If the answer to the first question is vague, that is usually enough information. The clinical utility of genetic tests is not an abstraction: it is whether the result leads to a different, better decision, and you are entitled to ask exactly that before you swab.

Genome-based diagnostics FAQ

What does clinical utility of genetic tests mean?

Whether using the test leads to a decision that improves outcomes. It sits above analytical validity, which is technical accuracy, and clinical validity, which is whether the variant genuinely relates to the condition. It is the hardest bar and the one insurers focus on.

Is whole exome sequencing better than a gene panel?

Not automatically. Exome sequencing reads the protein-coding regions and is valuable in unexplained rare disease, especially as a trio with both parents. Broader testing also produces more uncertain findings, so the right test depends on the clinical question.

What should I do about a variant of uncertain significance?

Nothing clinical on its own. A VUS is not a diagnosis and should not drive treatment. Keep it on record, continue screening justified by your personal and family history, and ask about reanalysis after a couple of years.

Can direct to consumer genetic testing rule out BRCA risk?

No. Consumer arrays check specific pre-selected positions, so a report covering three common BRCA variants misses thousands of other pathogenic variants. A negative consumer result is not reassurance, and clinically important results need confirmation in a clinical laboratory.

Does pharmacogenomic testing predict disease?

No. It reports how your body is likely to process certain medicines. It does not diagnose any condition or estimate your risk of developing one, which is a different category of genome-based diagnostics entirely.

Are my genetic results protected?

Federal law prohibits health insurers and employers from using genetic information to discriminate in most circumstances, but it does not cover life, disability or long-term care insurance. Read each laboratory’s data policy before testing.